Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • United Therapeutics sales and marketing update

    United Therapeutics Corp. (NASDAQ:UTHR), Silver Spring, Md. Business: Cancer The U.K.s NICE issued final draft guidance recommending against Unituxin dinutuximab from United Therapeutics to treat high-risk neuroblastoma…

    Published on 7/25/2016
  • BioDelivery sales and marketing update

    BioDelivery Sciences International Inc. (NASDAQ: BDSI), Raleigh, N.C. Business: Neurology, Drug delivery BioDelivery said an undisclosed managed care plan made Bunavail buprenorphine/naloxone its preferred treatment for…

    Published on 7/18/2016
  • Bristol-Myers, Gilead sales and marketing update

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Infectious Massachusetts Medicaid agency MassHealth said it will make Gileads Harvoni ledipasvir/…

    Published on 7/18/2016
  • Citius Pharmaceuticals sales and marketing update

    Citius Pharmaceuticals Inc. (OTCQB:CTXR), Maynard, Mass. Business: Endocrine/Metabolic, Infectious, Gastrointestinal Citius said it will discontinue FDA-approved Suprenza phentermine orally disintegrating tablets to …

    Published on 7/18/2016
  • Ferring sales and marketing update

    Ferring Pharmaceuticals A/S, Saint-Prex, Switzerland Business: Cancer The U.K.s NICE issued final draft guidance recommending the use of Firmagon degarelix from Ferring to treat advanced hormone-dependent prostate …

    Published on 7/18/2016
  • Celgene sales and marketing update

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer The U.K.s NICE issued a final appraisal determination (FAD) recommending against the use of Vidaza azacitidine from Celgene to treat patients at least 65 years …

    Published on 7/11/2016
  • Eli Lilly, Novartis sales and marketing update

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Endocrine/Metabolic, Cardiovascular Harvard Pilgrim Health Care Inc. (Boston, Mass.) will reimburse Lillys …

    Published on 7/11/2016
  • Hetero Drugs sales and marketing update

    Hetero Drugs Ltd., Hyderabad, India Business: Cancer, Biosimilars Hetero launched Cizumab, a biosimilar of Avastin bevacizumab, in India to treat metastatic colorectal cancer (mCRC). Hetero said the maximum retail price…

    Published on 7/11/2016
  • MDxHealth sales and marketing update

    MDxHealth S.A. (Euronext:MDXH), Liege, Belgium Business: Diagnostic MDxHealth said Americas Choice Provider Network Inc. (ACPN) (Henderson, Nev.) and Fortified Provider Network Inc. (FPN) (Scottsdale, Ariz.) will cover …

    Published on 7/11/2016
  • Pfizer sales and marketing update

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cancer The U.K.s NICE issued a final appraisal determination (FAD) recommending the use of Bosulif bosutinib from Pfizer to treat chronic, accelerated and blast phase …

    Published on 7/11/2016
  • Spectral Medical sales and marketing update

    Spectral Medical Inc. (TSX:EDT; OTCQX:EDTXF), Toronto, Ontario Business: Infectious FDA accepted Spectrals expanded access program for Toraymyxin to treat endotoxemic septic shock under a compassionate use program. …

    Published on 7/11/2016
  • AstraZeneca sales and marketing update

    AstraZeneca plc (LSE:AZN; NYSE: AZN), London, U.K. Business: Cancer Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in an early benefit assessment that added benefit of Tagrisso osimertinib …

    Published on 6/27/2016
  • Collegium sales and marketing update

    Collegium Pharmaceutical Inc. (NASDAQ:COLL), Canton, Mass. Business: Neurology Collegium launched Xtampza ER oxycodone extended-release in the U.S. to manage pain severe enough to require daily, around-the-clock, long-…

    Published on 6/27/2016
  • Eli Lilly sales and marketing update

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Cancer Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in two early benefit assessments that Cyramza ramucirumab from Lilly has minor …

    Published on 6/27/2016
  • Exelixis, Genentech, Roche sales and marketing update

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Cancer The U.K.s NICE issued draft guidance recommending …

    Published on 6/27/2016
  • Novartis sales and marketing update

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Cardiovascular Germanys Institute for Quality and Efficiency in Health Care (IQWiG) issued a dossier assessment addendum stating that heart failure drug …

    Published on 6/27/2016
  • Roche, Tib Molbiol sales and marketing update

    Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Tib Molbiol GmbH, Berlin, Germany Business: Diagnostic The companies launched the LightMix Modular Zika Virus Assay to detect the Zika virus in patients living in …

    Published on 6/27/2016
  • Shield Therapeutics sales and marketing update

    Shield Therapeutics plc (LSE:STX), London, U.K. Business: Hematology Shield launched Feraccru ferric maltol in the U.K. to treat adults with iron deficiency anemia associated with inflammatory bowel disease (IBD). The …

    Published on 6/27/2016
  • Theradiag, Miraca sales and marketing update

    Theradiag S.A. (Euronext:ALTER), Marne La Vallee, France Miraca Holdings Inc. (Tokyo:4544), Tokyo, Japan Business: Diagnostic Miracas Miraca Life Sciences subsidiary launched in the U.S. four assays derived from …

    Published on 6/27/2016
  • Vertex sales and marketing update

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass. Business: Pulmonary The U.K.s NICE issued a final appraisal determination (FAD) recommending against the use of Orkambi lumacaftor/ivacaftor from Vertex to treat …

    Published on 6/27/2016
  • Anika sales and marketing update

    Anika Therapeutics Inc. (NASDAQ:ANIK), Bedford, Mass. Business: Autoimmune Anika launched Cingal in Hungary, Poland, Germany and the Czech Republic to treat pain associated with osteoarthritis. The sodium hyaluronate …

    Published on 6/20/2016
  • Boehringer Ingelheim, Eli Lilly sales and marketing update

    Boehringer Ingelheim GmbH, Ingelheim, Germany Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Endocrine/Metabolic Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in two separate …

    Published on 6/20/2016
  • Counsyl sales and marketing update

    Counsyl Inc., South San Francisco, Calif. Business: Diagnostic, Cancer Counsyl expanded its Inherited Cancer Screen to test up to 36 genes associated with increased risk for cancer. The test, which uses a small saliva …

    Published on 6/20/2016
  • Protagen sales and marketing update

    Protagen AG, Dortmund, Germany Business: Diagnostic Protagen launched its Multilisa CENP-B, Multilisa Scl-70 and Multilisa BICD2 ELISA assays to diagnose systemic sclerosis. Multilisa CENP-B and Multilisa Scl-70 provide…

    Published on 6/20/2016
  • Teva sales and marketing update

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Neurology Teva recalled all pharmacy-level inventory of migraine drug Zecuity sumatriptan in the U.S. and suspended sales and marketing …

    Published on 6/20/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993